drugset / Trial / NCT04291105
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment. (CRC and melenoma cohorts are now closed to new patients)
Timeline
- Start
- 2020-04-24
- Primary completion
- 2026-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cemiplimab | Monoclonal antibody | — | Intravenous |
| Subject | VV1 | Unknown | — | Other |